BAM
MDGL icon

Blueshift Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Blueshift Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,226
Closed -$406K – 542
2025
Q1 		$406K Buy
+1,226
New +$403K 0.16% 203
2024
Q4 		– Sell
-1,852
Closed -$393K – 456
2024
Q3 		$393K Buy
+1,852
New +$474K 0.1% 231
2023
Q3 		– Sell
-3,139
Closed -$725K – 369
2023
Q2 		$725K Buy
3,139
+808
+35% +$219K 0.28% 90
2023
Q1 		$565K Buy
+2,331
New +$635K 0.24% 123
2022
Q2 		– Sell
-4,348
Closed -$427K – 885
2022
Q1 		$427K Buy
+4,348
New +$367K 0.04% 490

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return